Headline News

All stages of research on Alzheimer’s disease and related dementias should include increased public and participant involvement so the benefits are seen across diverse populations, according to a position paper in Alzheimer’s & Dementia.

CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported.

The FDA approved revumenib for the treatment of certain patients with advanced acute leukemia.

CHICAGO — Emailed messages emphasizing the CV benefits of influenza vaccination improved vaccine uptake among older and younger adults in Denmark, particularly among more vulnerable patients with a history of acute MI, researchers reported.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses controversies surrounding the use of complement inhibitors for the treatment of geographic atrophy.

Clonal hematopoiesis did not occur significantly more often among patients who received hematopoietic stem cell transplantation than their donors, according to findings of a correlative laboratory study.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights current challenges within the EGFR-mutated lung cancer space.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, offers advice to new residents seeing patients with EGFR-mutated lung cancer.

J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, spoke with Healio about monitoring patients with recurrent EGFR-mutated lung cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights important takeaways for interventional pulmonologists and other providers who may see patients with EGFR-mutated lung cancer.